CURING LOCALIZED IMMUNE CONDITIONS
beginning with Type 1 diabetes — built for much more
At Rezq Bio, our mission is to re-educate the immune system — not suppress it
We have engineered a platform that pairs two distinct delivery modalities with an indication-agnostic architecture, facilitating rapid expansion across autoimmune and transplant landscapes with minimal modification
T1D IS A global PROBLEM WITH NO SOLUTION
64k
New U.S. Diagnoses Annually
2M
Patients Currently in the U.S.
18M
Patients Worldwide by 2040
$85B
Economic Impact Globally
NO LONGEr A JUVENILE CONDITION
In a 2023 study from Johns Hopkins Bloomberg School of Public Health:
● Up to 62% of T1D cases develop in patients older than 20 (median 24 years)
● 37% of patients were diagnosed after 30 years
LACK OF EFFECTIVE TREATMENTS
There are no FDA-approved therapies for TID proven to…
● Prevent disease onset
● Arrest its progression or
● Restore insulin production safely
treatment options
platform
Dendritic cells are the master regulators of the immune system — capable of creating either an inflammatory or tolerant environment
Our platform harnesses this regulatory power, converting dendritic cells from a mature, inflammatory state (mDC) into an immature, tolerogenic state (iDC)
Autologous cell therapy — generated ex vivo, with clinically established human safety and negligible side effects
Microsphere delivery — replicates our cell therapy in situ, with equivalent preclinical performance and no cell harvesting required
Regional targeting — addresses local inflammation directly rather than suppressing systemic immunity, enabling both autoimmune treatment and cellular graft protection with minimal therapeutic modification
The result: a multi-condition, dual-delivery, dual-application foundation built for rapid expansion
Pipeline
Rezq's pipeline is led by our Phase 1B/2A ready cell therapy for early onset Type 1 Diabetes — our lighthouse indication. T1D validates our approach both as a monotherapy for localized autoimmune disease and as a combination therapy protecting islet cell grafts from immune attack
Our microsphere-based delivery system applies the same tolerogenic principles in a patient-ready, shelf-stable format — eliminating the cell manufacturing process entirely and expanding the scope and scale of our therapies
people
We have built careers in healthcare and are passionate about curing T1D and autoimmune disease
Board and Advisory
We are fortunate to have an accomplished Board and Advisory that believe in our team, science and mission to treat autoimmune disease
